Cargando…
Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India
Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a global health problem, India being the second most affected country. The kinetics of antibody response to SARS-CoV-2 in Indian population is not studied yet. To understand serological resp...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212795/ https://www.ncbi.nlm.nih.gov/pubmed/34177138 http://dx.doi.org/10.1007/s12291-021-00986-x |
_version_ | 1783709707882463232 |
---|---|
author | Chidananda, Mohana Kumari Zohmangaihi, Deepy Ram, Sant Soni, Shiv Lal Suri, Vikas Malhotra, Pankaj Jassal, Ravjit Singh Kaur, Jyotdeep Verma, Indu Sharma, Sadhna |
author_facet | Chidananda, Mohana Kumari Zohmangaihi, Deepy Ram, Sant Soni, Shiv Lal Suri, Vikas Malhotra, Pankaj Jassal, Ravjit Singh Kaur, Jyotdeep Verma, Indu Sharma, Sadhna |
author_sort | Chidananda, Mohana Kumari |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a global health problem, India being the second most affected country. The kinetics of antibody response to SARS-CoV-2 in Indian population is not studied yet. To understand serological response in relation to age, gender, time period and severity of disease, Roche Elecsys anti-SARS-CoV-2 test was used which analysed both IgM and IgG. One hundred and three COVID-19 patients were enrolled. Seropositivity was seen in 64% of patients, with 33% at ≤ 7 days, 62% between 8 and 15 days and 81% at ≥ 16 days from the time of admission. Men (65%) showed higher antibody response than women (59%), whereas no difference was observed in seropositivity with respect to age of the patients. Dynamics of antibody responses revealed individual variations. Patients in ICU had higher antibody reactivity with 67% positivity as compared to 60% positivity in non-ICU patients. Kinetics of antibody response during COVID-19 disease varied in relation to gender, age, time period and severity and these factors might play an important role in treatment and control of COVID-19. |
format | Online Article Text |
id | pubmed-8212795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer India |
record_format | MEDLINE/PubMed |
spelling | pubmed-82127952021-06-21 Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India Chidananda, Mohana Kumari Zohmangaihi, Deepy Ram, Sant Soni, Shiv Lal Suri, Vikas Malhotra, Pankaj Jassal, Ravjit Singh Kaur, Jyotdeep Verma, Indu Sharma, Sadhna Indian J Clin Biochem Original Research Article Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a global health problem, India being the second most affected country. The kinetics of antibody response to SARS-CoV-2 in Indian population is not studied yet. To understand serological response in relation to age, gender, time period and severity of disease, Roche Elecsys anti-SARS-CoV-2 test was used which analysed both IgM and IgG. One hundred and three COVID-19 patients were enrolled. Seropositivity was seen in 64% of patients, with 33% at ≤ 7 days, 62% between 8 and 15 days and 81% at ≥ 16 days from the time of admission. Men (65%) showed higher antibody response than women (59%), whereas no difference was observed in seropositivity with respect to age of the patients. Dynamics of antibody responses revealed individual variations. Patients in ICU had higher antibody reactivity with 67% positivity as compared to 60% positivity in non-ICU patients. Kinetics of antibody response during COVID-19 disease varied in relation to gender, age, time period and severity and these factors might play an important role in treatment and control of COVID-19. Springer India 2021-06-18 2021-10 /pmc/articles/PMC8212795/ /pubmed/34177138 http://dx.doi.org/10.1007/s12291-021-00986-x Text en © Association of Clinical Biochemists of India 2021, corrected publication 2021 |
spellingShingle | Original Research Article Chidananda, Mohana Kumari Zohmangaihi, Deepy Ram, Sant Soni, Shiv Lal Suri, Vikas Malhotra, Pankaj Jassal, Ravjit Singh Kaur, Jyotdeep Verma, Indu Sharma, Sadhna Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India |
title | Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India |
title_full | Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India |
title_fullStr | Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India |
title_full_unstemmed | Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India |
title_short | Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India |
title_sort | combined analysis of anti sars-cov-2 igg and igm responses in covid19 patients in india |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212795/ https://www.ncbi.nlm.nih.gov/pubmed/34177138 http://dx.doi.org/10.1007/s12291-021-00986-x |
work_keys_str_mv | AT chidanandamohanakumari combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia AT zohmangaihideepy combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia AT ramsant combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia AT sonishivlal combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia AT surivikas combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia AT malhotrapankaj combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia AT jassalravjitsingh combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia AT kaurjyotdeep combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia AT vermaindu combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia AT sharmasadhna combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia |